Newspaper Publication of Un-audited Financial Results for the quarter ended 30th June, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Genpharmasec Limited informed BSE that its unaudited Q1 FY26 financial results (quarter ended 30 June 2025) were published in 'Active Times' (English) and 'Mumbai Lakshadeep' (Marathi) on 8 August 2025, in line with SEBI LODR Regulations 30 and 47. On a consolidated basis, total income from operations fell sharply to ₹576.20 Lakhs versus ₹3,676.40 Lakhs in Q1 FY25 — roughly an 84% year-on-year drop. Consolidated net profit after tax stood at ₹28.68 Lakhs (vs ₹128.12 Lakhs YoY), with EPS of ₹0.05. Standalone numbers showed total income of ₹583.08 Lakhs (vs ₹3,630.16 Lakhs YoY) and a profit after tax of ₹58.87 Lakhs, indicating subsidiaries dragged down overall profitability. The board approved the results on 6 August 2025.
The steep YoY revenue decline is likely to concern investors, even though the company remained profitable at the standalone level. Shareholders should watch for management's explanation of the sharp revenue drop and any commentary on subsidiary performance in the detailed results.